What is Glepaglutide?
Glepaglutide (development code ZP1848) is a long-acting GLP-2 receptor agonist developed by Zealand Pharma for short bowel syndrome (SBS). It is dosed as twice-weekly subcutaneous injection — a middle ground between teduglutide's daily dosing and apraglutide's weekly dosing.
Glepaglutide's Phase 3 EASE-1 trial in adults with SBS met primary endpoints, but Zealand Pharma announced on December 19, 2024 that the FDA had issued a Complete Response Letter (CRL) requesting additional clinical trial data. The development path forward is uncertain pending Zealand's response and any further trial requirements.
Mechanism of Action
Glepaglutide is a 35-amino-acid synthetic GLP-2 analogue engineered for:
- DPP-4 resistance at the N-terminal alanine
- Extended half-life through structural modifications (residue substitutions and amidation)
- Twice-weekly dosing — half-life supports SC dosing every 3-4 days
Pharmacology is mechanistically equivalent to other GLP-2 analogues — promoting intestinal mucosal proliferation, increasing absorptive capacity, and reducing parenteral support needs in SBS patients.
Clinical Evidence
EASE-1 Phase 3 trial:
- Adults with SBS dependent on parenteral support, randomized to glepaglutide twice-weekly vs placebo for 24 weeks
- Significant reduction in weekly parenteral support volume vs placebo
- Tolerability consistent with GLP-2 class (abdominal pain, GI symptoms)
EASE-2 and EASE-3 — supportive studies in pediatric and additional adult populations
FDA Complete Response Letter
In December 2024, the FDA issued a CRL for the glepaglutide NDA, requesting additional clinical data. Per Zealand Pharma's announcement:
- The CRL did not raise safety concerns
- Additional efficacy data from a larger or longer-duration trial is required
- Zealand is evaluating its response strategy and any potential refile timeline
Pipeline Status
- Phase 3 EASE-1 positive
- FDA CRL (December 2024) — requires additional data
- EU Marketing Authorization Application in 2025
- Resubmission timing uncertain
Place in Future Therapy
If glepaglutide eventually achieves FDA approval, the SBS market would have three GLP-2 options:
| Drug | Sponsor | Dosing | FDA Status |
|---|---|---|---|
| Teduglutide (Gattex) | Takeda | Daily SC | Approved 2012 |
| Glepaglutide | Zealand Pharma | Twice-weekly SC | Phase 3 / CRL Dec 2024 |
| Apraglutide | Ironwood | Once-weekly SC | Phase 3 / NDA pending |
The competitive dynamics depend heavily on:
- Whether Zealand can address the CRL with available data or new trials
- Apraglutide's NDA review timeline
- Pricing and access patterns in the rare-disease SBS market
Safety Profile
Phase 3 adverse events were typical of the GLP-2 class:
- Abdominal pain, nausea, GI symptoms
- Injection-site reactions
- Cholelithiasis monitoring required
- Pre-treatment colonoscopy standard given the class warning for proliferative effects
Why It Matters
Glepaglutide is part of the broader story of how the rare disease SBS-IF market is being reshaped by next-generation GLP-2 chemistry. The market has been dominated by teduglutide for over a decade; weekly and twice-weekly alternatives offer meaningful patient-experience improvements. The FDA CRL highlights that even strong Phase 3 efficacy data can require additional confirmation when the patient population is small and the long-term outcomes (PN reduction, enteral autonomy) need extended follow-up.